Literature DB >> 22906947

Immunotherapy in ovarian cancer.

Gina M Mantia-Smaldone1, Bradley Corr, Christina S Chu.   

Abstract

Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths anticipated in 2012. While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 y. Host anti-tumor immune responses are associated with a significant improvement in overall survival for women with ovarian cancer. By bolstering these responses, it may therefore be possible to significantly influence the prognosis of women with this lethal disease. In this review, we will focus on innovative immune-based strategies which are currently being investigated in the treatment of ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22906947      PMCID： PMC3579897          DOI： 10.4161/hv.20738

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  87 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.

Authors:  T G Ehlen; P J Hoskins; D Miller; T L Whiteside; C F Nicodemus; B C Schultes; K D Swenerton
Journal:  Int J Gynecol Cancer       Date:  2005 Nov-Dec       Impact factor: 3.437

3.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

4.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study.

Authors:  C F Molthoff; H M Prinssen; P Kenemans; A C van Hof; W den Hollander; R H Verheijen
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

6.  Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Authors:  Paul Sabbatini; Jakob Dupont; Carol Aghajanian; Felicia Derosa; Elizabeth Poynor; Sybil Anderson; Martee Hensley; Phillip Livingston; Alexia Iasonos; David Spriggs; William McGuire; Silke Reinartz; Sally Schneider; Cathy Grande; Shashikant Lele; Kerry Rodabaugh; James Kepner; Soldano Ferrone; Kunle Odunsi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

7.  Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.

Authors:  R P Edwards; W Gooding; B C Lembersky; K Colonello; R Hammond; C Paradise; C D Kowal; A J Kunschner; M Baldisseri; J M Kirkwood; R B Herberman
Journal:  J Clin Oncol       Date:  1997-11       Impact factor: 44.544

8.  Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.

Authors:  B M Sandmaier; D V Oparin; L A Holmberg; M A Reddish; G D MacLean; B M Longenecker
Journal:  J Immunother       Date:  1999-01       Impact factor: 4.456

9.  Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Authors:  Anne M Ercolini; Brian H Ladle; Elizabeth A Manning; Lukas W Pfannenstiel; Todd D Armstrong; Jean-Pascal H Machiels; Joan G Bieler; Leisha A Emens; R Todd Reilly; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2005-05-09       Impact factor: 14.307

10.  Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.

Authors:  J Connor; R Bannerji; S Saito; W Heston; W Fair; E Gilboa
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307
View more
  20 in total

1.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

Review 2.  Tumor cell lysates as immunogenic sources for cancer vaccine design.

Authors:  Fermín E González; Alejandra Gleisner; Felipe Falcón-Beas; Fabiola Osorio; Mercedes N López; Flavio Salazar-Onfray
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer.

Authors:  Mingxing Sui; Lihui Si; Tianmin Xu; Manhua Cui
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

4.  A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

Authors:  Ronald D Alvarez; Michael W Sill; Susan A Davidson; Carolyn Y Muller; David P Bender; Robert L DeBernardo; Kian Behbakht; Warner K Huh
Journal:  Gynecol Oncol       Date:  2014-04-04       Impact factor: 5.482

5.  Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer.

Authors:  Lihong Zhang; Xuejing Yang; Zhen Sun; Jiali Li; Hui Zhu; Jing Li; Yan Pang
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

6.  Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.

Authors:  Yang Zeng; Binghao Li; Yingying Liang; Patrick M Reeves; Xiying Qu; Chongzhao Ran; Qiuyan Liu; Michael V Callahan; Ann E Sluder; Jeffrey A Gelfand; Huabiao Chen; Mark C Poznansky
Journal:  FASEB J       Date:  2019-02-25       Impact factor: 5.834

7.  Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Haolin Wang; Fandong Meng; Jie Li; Shulan Zhang
Journal:  J Transl Med       Date:  2015-07-29       Impact factor: 5.531

8.  PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Xin Wang; Dali Cheng; Zhijun Xia; Meng Luan; Shulan Zhang
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Dali Cheng; Zhijun Xia; Meng Luan; Liangliang Wu; Gang Wang; Shulan Zhang
Journal:  J Transl Med       Date:  2013-09-17       Impact factor: 5.531

10.  Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.

Authors:  Huafeng Wei; Likun Zhao; Wei Li; Kexing Fan; Weizhu Qian; Sheng Hou; Hao Wang; Min Dai; Ingegerd Hellstrom; Karl Erik Hellstrom; Yajun Guo
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.